2023 - Diagnostic Products and Solutions Supplier-Medlere

News

Through tireless work and reinvesting profits back into our company, we developed new products and earned recognition and praise from the industry. As we look to the future, we aim to continue pushing the boundaries of innovation and excellence in our industry, with the ultimate goal of making a positive impact on the health and wellbeing of people everywhere.

You are here: Home / News / 2023

Rapid Diagnostic Test for Respiratory Infections

With the onset of winter, there is an increase in acute respiratory infections caused by various respiratory pathogens recently. As in other infectious processes, swift accurate diagnosis is associated with more targeted and effective treatment, lower transmission of the disease and, often, a reduction in its duration. To combat rise of acute respiratory infections, Medlere provides rapid quantitative tests for respiratory infections basing on immunofluorescence technology, which delivers rapid and accurate results within minutes. • RSV (Respiratory Syncytial Virus) • ADV (Adenovirus) • Influenza A/B • SARS-CoV-2 • SARS-CoV-2/InfluenzaA/B • Mycoplasmsa Pneumoniae

12/ 01 / 2023

The Crucial Role of Immunofluorescence Assay in the IVD Industry

Medlere's Fluorescence Immunoassay sets a new standard for Point-of-Care Testing (POCT) solutions. This system delivers rapid and accurate results within minutes. Designed with user-friendliness in mind, our Fluorescence Immunoassay empowers healthcare professionals with a reliable tool to diagnose a wide range of diseases and conditions, elevating patient care and treatment outcomes.

03/ 28 / 2022

Who We Are

With the ultimate goal of making a positive impact on the health and wellbeing of people everywhere.

Quick Links

Product Category

Address: 291 Brighton Road South Croydon United Kingdom Cr2 6Eq E-mail: info@medlere.com Tel.: +447565748991

The content on the Medlere website may showcase some of our forthcoming care offerings, which are currently under development. Please note that these offerings are subject to completion of the development process and may require regulatory authorization, clearance, or approval before they can be made available for commercial use.